Seeking Alpha
View as an RSS Feed

Bret Jensen  

View Bret Jensen's Comments BY TICKER:
A, AA, AAPL, ABB, ABT, ABTL, ABX, ACLS, ACMP, ACTG, ACTV, ADBE, ADSK, AEP, AGCO, AGEN, AGU, AHH, AHT, AIG, AKS, ALJ, ALL, ALR, AMAT, AMGN, AMKR, AMTD, AMZG, AMZN, ANF, ANV, APA, APC, APL, ARCP, ARII, ARLP, ARO, ARP, ATRS, ATSG, ATVI, ATW, AU, AVGO, AVNR, AXAS, AXTI, AYR, AZN, BA, BAC, BAS, BAX, BBBY, BBEP, BBRY, BBT, BBW, BBY, BCEI, BGFV, BHI, BIDU, BIG, BIIB, BIOL, BK, BKCC, BKH, BKW, BLK, BMO, BMR, BNS, BP, BRCD, BRCM, BRKS, BTU, BWP, BX, BYI, C, CALL, CAT, CBI, CBOU, CDE, CELG, CEO, CERS, CGIX, CGR, CHK, CHL, CHMT, CJES, CLDT, CLF, CLMT, CLR, CMG, CMI, CMLP, CNAT, CNDO, CNP, CNQ, CNX, COF, COG, COH, COOL, COP, CORT, CPE, CPIX, CPSI, CRM, CROX, CRUS, CRZO, CSCO, CSX, CTCM, CVE, CVS, CVX, CXPO, CXS, CY, DAKT, DAN, DBC, DD, DDE, DECK, DENN, DG, DISH, DK, DNR, DO, DOW, DRH, DRIV, DSCO, DTLK, DTV, DUSA, DVAX, DVN, DVR, DWA, DXLG, E, EBAY, ECA, EDR, ELLI, ELY, EMC, END, ENDP, EOG, EOX, EPAM, EPAX, EPB, EPR, EQIX, EQM, EROC, ESIO, ESV, ETE, ETN, ETP, ETRM, EVEP, EWZ, EXK, EXLP, EXPE, EXXI, F, FANG, FB, FCH, FCX, FDX, FIG, FLL, FLY, FOLD, FOSL, FRD, FSC, FSII, FURX, FWLT, FXCM, GBX, GCOM, GE, GEF, GEOY, GERN, GES, GEVA, GFI, GILD, GLP, GLUU, GLW, GM, GNW, GOOG, GOOGL, GPOR, GPS, GS, GSK, GSM, GSS, GTATQ, GTE, HAL, HBM, HCBK, HCLP, HEP, HERO, HES, HFC, HIG, HL, HLF, HLX, HMA, HON, HOS, HP, HPQ, HPT, HRS, HRZN, HTA, HTGC, HURN, HZNP, IACI, IAG, IGTE, IMOS, INN, INT, INTC, INVN, IO, IPGP, IQNT, IRDM, IRET, IRT, ISRG, ITRI, ITT, IVAN, JAZZ, JDSU, JNJ, JNPR, JOY, JPM, KBH, KBR, KCG, KEG, KERX, KFY, KKR, KLAC, KLIC, KO, KOG, KONA, KR, KRG, KRO, LAD, LCI, LGCY, LIFE, LIME, LINE, LLL, LLNW, LLY, LMOS, LMT, LNCO, LNKD, LO, LOCO, LOW, LPRI, LSI, LUK, LULU, LVS, LXP, LYB, M, MANT, MCEP, MCHX, MCP, MDR, MDT, MELI, MEMP, MET, MHR, MITL, MMLP, MMP, MNK, MO, MOD, MOS, MPC, MPO, MPW, MRCY, MRGE, MRK, MRO, MRVL, MS, MSFT, MT, MTDR, MTOR, MTSN, MU, MUR, MXIM, MYL, MYRG, NAVB, NBL, NBR, NE, NEE, NEM, NEON, NFLX, NFX, NGLS, NGPC, NILE, NOG, NOK, NOV, NSC, NSPH, NTAP, NTSP, NUAN, NVAX, NVDA, NVS, NWY, NXPI, NYCB, NYX, OAS, OCN, OCZ, OHI, OIS, OKS, OPEN, OPLK, ORAN, ORCL, ORIG, ORLY, OUTR, OVTI, OXY, OZM, PAA, PAAS, PACD, PACR, PANW, PAYX, PBF, PBH, PBI, PBY, PCLN, PDH, PDLI, PDS, PEET, PEG, PES, PETM, PETS, PFE, PFMT, PGEM, PH, PM, PNG, PNK, PNRA, POM, POT, PRTA, PSX, PTEN, PULB, PVR, PWER, QCCO, QCOM, QLGC, QLTY, QRE, QUMU, R, RAIL, RAX, RCL, RDWR, REGN, RES, REXX, RF, RFMD, RIG, RIGL, RIO, RNN, ROC, ROSE, ROVI, RPRX, RRD, RSTI, RTEC, RTN, RUE, RUTH, RVBD, SAM, SARA, SBRA, SCLN, SCMR, SCO, SDRL, SEAC, SFY, SHOR, SIGA, SIMG, SIMO, SIRI, SKUL, SLB, SLCA, SM, SMCI, SN, SNH, SNY, SODA, SPLK, SPLS, SPN, SPPI, SPRT, SPY, SQNM, SSH, SSNLF, STI, STJ, STMP, STO, STT, STX, SUNE, SVU, SWFT, SWKS, SYNA, SYRG, T, TAL, TAP, TBT, TCAP, TDW, TEF, TER, TESO, TEVA, TEX, TGX, TICC, TIVO, TKR, TLLP, TOT, TPC, TPLM, TQNT, TRLG, TRN, TSLA, TSO, TST, TSYS, TTI, TWI, TWX, UA, UNH, UNIS, UPL, USB, V, VALE, VELTF, VICL, VLO, VMW, VNR, VOD, VRA, VXX, VZ, WAC, WAG, WDC, WEN, WFC, WFT, WHR, WIFI, WLL, WMT, WRES, XEC, XOM, XRX, YELP, YHOO, Z, ZAGG, ZEUS, ZIXI, ZLTQ, ZNGA
Latest  |  Highest rated
  • iRobot: This Week's Small Cap Focus Stock [View article]
    Have no idea, but would make sense for larger player that wants to get in space. Should do fine as a standalone as well. JMTC
    Jul 30, 2015. 09:39 AM | Likes Like |Link to Comment
  • Ford: Exceptional Value In An Overbought Market [View article]
    Low end of China getting hit hard, Ford and GM are doing solidly with their more luxury offerings while Japanese getting the brunt of slowdown. Article in WSJ yesterday on that.
    Jul 30, 2015. 08:17 AM | 3 Likes Like |Link to Comment
  • High-Flying Synergy Pharmaceuticals Still Has Upside [View article]
    Boom goes the dynamite....stock up more than 20% in pre-market.

    Two Phase 3 trials evaluating two doses (3 mg and 6 mg) Synergy Pharmaceuticals' (NASDAQ:SGYP) plecanatide in 1337 adult patients with chronic idiopathic (cause unknown) constipation (CIC) successfully achieved the primary efficacy endpoints.On a preliminary basis, the proportion of patients in the intent-to-treat population who were durable overall responders in each dosage cohort was distinctly greater than placebo during the 12-week treatment period (3 mg: 20.1%; 6 mg: 20.0%; placebo: 12.8%; p=0.004 for both doses). The results were statistically significant. The durable overall responder endpoint is the current FDA standard for clearance in the U.S. for CIC.Plecanatide was safe and well-tolerated at both doses. The most common adverse event was diarrhea (3 mg: 3.2%; 6 mg: 4.5%). 20 patients (1.4%) experienced serious adverse events, but there was no imbalance between the treatment groups.The company intends to present the data at future medical conferences. It plans to file a New Drug Application (NDA) with the FDA in January.Plecanatide is a uroguanylin analogue. Uroguanylin is a naturally occurring gastrointestinal (GI) peptide produced in the small intestine that plays a key role in GI activity including the movement of fluid required for normal digestion.
    Jul 30, 2015. 08:09 AM | 1 Like Like |Link to Comment
  • Ford: Exceptional Value In An Overbought Market [View article]
    Absolutely.
    Jul 29, 2015. 09:47 PM | Likes Like |Link to Comment
  • Gilead: Buy The Dip Before Tuesday's Results [View article]
    One of my top G.A.R.P. picks within the Blue Chip Gems portfolio which has done exceptionally well in a flat 2015 so far.
    Jul 29, 2015. 05:18 PM | Likes Like |Link to Comment
  • Ford: Exceptional Value In An Overbought Market [View article]
    If it can't now with basically all new line-up, it never will.
    Jul 29, 2015. 04:22 PM | Likes Like |Link to Comment
  • Has The Long Awaited Correction Begun? [View article]
    Until it doesn't which would be inflection point.
    Jul 29, 2015. 09:53 AM | 5 Likes Like |Link to Comment
  • Bailing Out Of Brazil [View article]
    Standard & Poor's has warned Brazil it could lose its coveted investment-grade rating in the coming year if fallout from a number of corruption investigations further stymies economic growth and implementation of austerity measures.The agency has now put the country's foreign currency rating, which is rated one notch above junk, on negative outlook for possible downgrade.The Brazilian real slid 2% to 3.43 per dollar following the announcement, its weakest level in more than 12 years.
    Jul 29, 2015. 05:46 AM | Likes Like |Link to Comment
  • Has The Long Awaited Correction Begun? [View article]
    25%. Biggest holding is GILD, which just crushed earnings again.
    Jul 28, 2015. 04:13 PM | 5 Likes Like |Link to Comment
  • Gilead: Buy The Dip Before Tuesday's Results [View article]
    On headline on CNBC, Gilead $3.15 a share in earnings vs $2.71 expected. Revenue also beats....
    Jul 28, 2015. 04:04 PM | 3 Likes Like |Link to Comment
  • Has The Long Awaited Correction Begun? [View article]
    Market has not done anything since then...some major sector rotations especially out of energy....only gains have been high momentum stocks without much earnings like NFLX, AMZN, etc..
    Jul 28, 2015. 02:13 PM | 4 Likes Like |Link to Comment
  • Gilead: Buy The Dip Before Tuesday's Results [View article]
    Usually SA turns around my articles within two hours....this seems to be have been a glitch.
    Jul 28, 2015. 12:33 PM | 1 Like Like |Link to Comment
  • Has The Long Awaited Correction Begun? [View article]
    Yep, outside of six stocks (NFLX, GOOG, AMZN, etc..)....almost every investor is down this year.
    Jul 28, 2015. 12:12 PM | 2 Likes Like |Link to Comment
  • Has The Long Awaited Correction Begun? [View article]
    AMGN still sports reasonable value. MYL worth a look after yesterday's big fall imho
    Jul 28, 2015. 10:18 AM | Likes Like |Link to Comment
  • Revisiting The Investment Case On Progenics Pharmaceuticals [View article]
    $PGNX....what is moving the stock today.

    Progenics Pharmaceuticals (NASDAQ:PGNX) jumps 22% premarket on increased volume in response to its announcement that the FDA has granted Breakthrough Therapy status to Azedra for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma (tumor of the adrenal gland) and paraganglioma. Phase 2b-stage Azedra also has Orphan Drug and Fast Track designations.Azedra (Ultratrace iobenguane I 131) is a highly specific activity form of the radiotherapeutic iobenquane I 131.BTD status provides for more intensive guidance from the FDA, the involvement of more senior agency personnel and a rolling review of the New Drug Application (NDA). Orphan Drug status provides for a seven-year period of market exclusivity for the indication, if approved.
    Jul 28, 2015. 09:57 AM | Likes Like |Link to Comment
COMMENTS STATS
11,493 Comments
12,857 Likes